Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 23, 2023

SELL
$191.51 - $216.16 $938,782 - $1.06 Million
-4,902 Reduced 3.12%
152,446 $32.3 Million
Q2 2023

Jul 26, 2023

SELL
$187.64 - $206.25 $6.88 Million - $7.57 Million
-36,690 Reduced 18.91%
157,348 $30.3 Million
Q1 2023

May 04, 2023

SELL
$127.59 - $203.08 $7.1 Million - $11.3 Million
-55,617 Reduced 22.28%
194,038 $39.3 Million
Q4 2022

Jan 31, 2023

BUY
$117.37 - $139.17 $102,464 - $121,495
873 Added 0.35%
249,655 $32.1 Million
Q4 2022

Jan 25, 2023

SELL
$117.37 - $139.17 $370,419 - $439,220
-3,156 Reduced 1.25%
248,782 $0
Q3 2022

Oct 31, 2022

SELL
$135.27 - $180.11 $484,672 - $645,334
-3,583 Reduced 1.4%
251,938 $34.5 Million
Q2 2022

Aug 02, 2022

SELL
$108.81 - $179.33 $5 Million - $8.24 Million
-45,970 Reduced 15.25%
255,521 $45.2 Million
Q1 2022

May 05, 2022

SELL
$119.61 - $157.85 $1.14 Million - $1.5 Million
-9,532 Reduced 3.06%
301,491 $43.4 Million
Q4 2021

Feb 02, 2022

SELL
$142.57 - $190.86 $792,831 - $1.06 Million
-5,561 Reduced 1.76%
311,023 $48.1 Million
Q3 2021

Oct 19, 2021

SELL
$142.45 - $169.82 $944,728 - $1.13 Million
-6,632 Reduced 2.05%
316,584 $53.8 Million
Q2 2021

Aug 02, 2021

SELL
$135.08 - $161.1 $99,689 - $118,891
-738 Reduced 0.23%
323,216 $51 Million
Q1 2021

May 12, 2021

SELL
$137.51 - $190.8 $3.74 Million - $5.19 Million
-27,180 Reduced 7.74%
323,954 $45 Million
Q4 2020

Jan 26, 2021

BUY
$164.63 - $211.93 $57.8 Million - $74.4 Million
351,134 New
351,134 $61.5 Million

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Pinnacle Associates LTD Portfolio

Follow Pinnacle Associates LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pinnacle Associates LTD with notifications on news.